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BACKGROUND: Tumor vascularity is a potential predictor of treatment outcomes in metastatic renal cell carcinoma
(mRCC), and contrast enhancement of tumors in computed tomography (CT) is correlated significantly with micro-
vessel density. In this study, the authors investigated whether tumor enhancement in contrast-enhanced CT (CECT) is
useful for predicting outcomes in patients with mRCC who are receiving antiangiogenic therapy. METHODS: Attenua-
tion values were reviewed retrospectively on CECT images of all metastatic lesions in 66 patients from February
2007 to November 2008. All patients received a tyrosine kinase inhibitor (either sunitinib or sorafenib). Tumor
response was evaluated on CECT studies every 12 weeks. The authors analyzed the association between contrast
enhancement and treatment outcomes, including objective response, tumor size reduction rate, time to response,
and time to progression. RESULTS: In 46 patients, 198 metastatic lesions were assessed. Tumor size was reduced in
140 lesions (70.7%) and was increased in 58 lesions (29.3%). The mean reduction in size was 23.8%. The overall mean
time to response and the time to progression were 8.6 months and 16.4 months, respectively. In multivariate analyses,
tumor enhancement and enhancement pattern were associated with objective responses (P ¼ .003 and P ¼ .028,
respectively). In addition, tumor enhancement was associated with tumor size reduction (P ¼ .004). In Cox propor-
tional hazards models, only tumor enhancement was associated significantly with the time to size reduction and pro-
gression-free survival (P ¼ .03 and P ¼ .015, respectively). CONCLUSIONS: Tumor enhancement on CECT images was
associated with treatment outcomes and was identified as a potential predictor of treatment outcomes after antian-
giogenic therapy in patients with mRCC. Cancer 2010;116:2332–42. VC 2010 American Cancer Society.
KEYWORDS: renal cell carcinoma, metastasis, targeted therapy, computed tomography, attenuation, contrast
enhancement, response, prognosis.
The incidence and mortality rates of renal cell carcinoma (RCC) have been rising steadily worldwide at a rate of2% to
3% per decade.1,2 The annual incidence of metastatic RCC (mRCC) in major European countries, the United States, and
Japan ranges from 1500 to 8600 cases.2 However, treatment options are few because of the high resistance of these tumors
to conventional chemotherapy and radiotherapy. Although cytokine-based therapies have produced response rates of 10%
to 20% in patients with mRCC, their overall clinical value is limited.3
Targeted therapy recently has evolved as a treatment for malignancy and has changed the treatment paradigms for
advanced or metastatic disease in several malignancies, including mRCC. This innovation is based on a better understand-
ing of cell signal transduction and the molecular pathways of growth factors and receptors associated with tumor
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angiogenesis. Targeted agents inhibit angiogenesis, reduc-
ing tumor growth and progression through the inhibition
of tyrosine kinase activity of growth factor receptors.
Treatment of mRCC with sunitinib and sorafenib has
improved response and prolonged progression-free sur-
vival significantly.4-7
Several clinical factors are associated with outcome
in patients with mRCC, including performance status,
disease-free interval, number of metastatic sites, and labo-
ratory variables like hemoglobin, calcium, and lactate de-
hydrogenase levels.8-10 Although recent studies suggest
that these factors remain pertinent,11-13 because cytokine-
based therapy and targeted therapy have different mecha-
nisms of action, optimal clinical factors associated with
outcomes of targeted therapy in mRCC should be rein-
vestigated. Theoretically, tumor vascularity may be a pre-
dictive factor for outcomes of targeted therapy.
Preliminary results with serum measures, including
plasma vascular endothelial growth factor (VEGF) and
circulating endothelial cells, have produced only modest
success and are in relatively early stages of refinement.14,15
Microvessel density may be an optimal predictive factor
for outcomes of antiangiogenic therapy, but the difficulty
of applying it to all lesions means that it has limited wide-
spread use in clinical practice.16 Other methods for the
assessment of tumor vascularity, such as molecular imag-
ing or measures of blood volume or flow change using
magnetic resonance imaging (MRI), have been proposed
but remain in the experimental stage.15,17-19
The imaging method that is used most commonly
to evaluate metastatic lesions during treatment is contrast-
enhanced computed tomography (CECT). Several studies
have demonstrated that tumor enhancement on CECT is
correlated significantly with microvessel density, a patho-
logic marker that represents tumor vascularity in
RCC.16,20 Therefore, contrast enhancement of metastatic
lesions may be a predictive factor for outcome after tar-
geted therapy in patients with mRCC. However, to our
knowledge, the association between tumor enhancement
on CECT and outcomes of targeted therapy has not been
investigated. In the current study, we examined whether
tumor enhancement on CECT could predict treatment
outcomes after targeted therapies in patients with mRCC.
MATERIALS AND METHODS
Patients
This retrospective study was approved by the institutional
review board of the Center (NCCNCS-09-217). By using
a kidney cancer database that was collected prospectively
by the Center, we identified patients who received tyro-
sine kinase inhibitor (TKI) therapy for mRCC from Feb-
ruary 2007 to November 2008. The inclusion of patients
in this study was subject to the following criteria: histo-
logic confirmation of a clear cell type tumor component
using tissue biopsies or resection of primary renal lesions,
the presence of measurable metastatic tumors that meas-
ured >10 mm in greatest dimension, the use of TKIs for
initial targeted therapy, at least 2 cycles of TKI therapy,
the existence of follow-up CECT images after the initial 2
cycles of TKI therapy, and the use of chest or abdominal
CECT scans as the follow-up imaging method. We iden-
tified 66 patients who received TKI therapy. Of these, 20
were excluded for the following reasons: follow-up of <2
cycles in 8 patients, discontinuation of TKIs because of
toxicity before 2 cycles in 6 patients, loss of follow-up
before the first response evaluation in 4 patients, and the
use of nonenhanced CT orMRI instead of CECT because
of impaired renal function in 2 patients. Forty-six patients
met the criteria for inclusion in this study.
Tyrosine Kinase Inhibitor Therapy
We followed the protocols of phase 3 trials of sunitinib
and sorafenib for administration schedules.4,5 The
patients received 1 of 2 treatment regimens: 1) sunitinib
maleate (Sutent; Pfizer Pharmaceuticals Inc., Seoul,
Korea) administered orally at a dose of 50 mg once daily,
taken without regard to meals, in 6-week cycles consisting
of 4 weeks of treatment followed by 2 weeks without treat-
ment; or 2) sorafenib (Nexavar; Bayer HealthCare Phar-
maceuticals, Inc., Seoul, Korea) administered orally at a
dose of 400 mg twice daily in continuous 6-week cycles.4,5
TKIs were discontinued temporarily when grade 3 or 4
toxicity occurred according to National Cancer Institute
Common Toxicity Criteria version 3.0, and continuation
depended on whether the patient recovered from toxicity.
Response was evaluated according to Response Evaluation
Criteria in Solid Tumors (RECIST) guidelines.21
Computed Tomography Imaging Protocol
Patients underwent baseline CECT scans before the ini-
tiation of antiangiogenic treatment and received CECT
scans for response evaluation of metastatic lesions every
12 weeks after treatment began, regardless of the TKI
administered. CT imaging was performed using 4-chan-
nel and 16-channel MDCT scanners (Mx 8000: Marconi
Medical Systems, Tel Aviv, Israel; and LightSpeed Pro 16:
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GE Healthcare, Milwaukee, Wis, respectively). Images
were obtained in a craniocaudal direction.22 A CT scan
was performed before contrast injection. Patients were
administered intravenous contrast material (Iopromide,
Ultravist 300; Schering, Berlin, Germany) through an
antecubital vein using a mechanical injector (120 mL at 3
mL per second). Scanning for early phase images began
35 seconds after the start of intravenous contrast injection
either from the lower thorax to the lower pelvis or from
the neck to the upper abdomen. The following scanning
parameters were used for the Light Speed Ultra CT scan-
ner: peak tube voltage, 120 kVp; tube current, 120 to 400
mA; rotation time, 0.5 seconds; reconstruction thickness,
2.5 mm; and detector configuration, 16-detector rows
with a pitch of 0.938. The following parameters were
used for the MX 8000 scanner: peak tube voltage, 120
kVp; tube current, 140 mA; rotation time, 0.75 seconds;
reconstruction thickness, 3.2 mm; and detector configura-
tion, 4-detector rows with a pitch of 1.75.
Evaluation of Tumor Enhancement
All images were examined using a picture archiving and
communication system, which displayed image data on
monitors, by 2 radiologists (D.C.J. and H.J.C.) with 6
years and 8 years of experience in uroradiology, respec-
tively. To obtain attenuation values, quantitative evalua-
tion of regional enhancement was performed by manual
measurements using a round or ovoid, manually control-
lable region of interest (ROI) placed in the center of meta-
static nodules by consensus between the 2 radiologists.
Circular ROIs >mm2 were drawn to encompass as much
of the nodule as possible, covering >50% of the nodule
but excluding peripheral areas to avoid partial volume
effects from adjacent normal parenchyma. In addition,
calcification, blood vessels, and necrotic and cystic areas
were excluded from ROI measurements as much as possi-
ble. The attenuation values of the ROIs were measured an
average of 3 times.
Data Collection
Baseline patient data, including age, sex, Karnofsky per-
formance status, history of primary tumor removal, histo-
logic type of the primary tumor, histologic type of
metastases, history of cytokine-based therapy, type of
TKI, number of metastases, and levels of serum hemoglo-
bin, serum calcium, corrected calcium,9 and lactate dehy-
drogenase, were collected from patient interviews and
reviews of medical records. Tumor characteristics, includ-
ing metastatic site, tumor size, growth pattern, existence
of necrosis, enhancement pattern, and quantitative con-
trast enhancement measurements, were evaluated from
reviews of the serial CECT images. Brain lesions were
excluded in this study. Blastic bone lesions were excluded
in principle; however, lytic bone lesions or mixed lytic-
blastic lesions with identifiable soft tissue components
that could be evaluated by CT were considered measura-
ble lesions when the soft tissue component fulfilled the
definition of measurability.23 Tumor size was defined as
the greatest dimension of the tumor lesion. Round or
lobulated tumors with clear margins were classified as
conglomerated, and tumors with irregular shapes or mar-
gins were classified as infiltrative. The existence of necrosis
was defined as the presence of a nonenhanced portion
within the tumor lesion. Enhancement patterns were clas-
sified as either homogeneous or heterogeneous. Homoge-
nous enhancement was defined as an even distribution of
contrast uptake within an enhanced portion of a lesion,
and heterogeneous enhancement was defined as an
unequal distribution of contrast uptake within an
enhanced portion of a lesion. A consensus between the 2
radiologists was required to classify each enhancement
pattern. Tumor enhancement was defined as the differ-
ence in Hounsfield units (HUs) between nonenhanced
and enhanced phases on CECT scans.
Statistical Analyses
The first endpoint of the study, the objective response of
individual metastatic lesions, was evaluated using 2 differ-
ent methods. Objective responses initially were classified
as either responsive or nonresponsive according to
RECIST guidelines. A chi-square test or Fisher exact test
was performed for binomial variables, and biserial correla-
tion analysis was used for continuous variables. Logistic
regression was used in multivariate analyses. Objective
response was considered a continuous variable, with the
tumor size reduction rate calculated as follows: (final
reduced size  initial size)/initial size. Independent Stu-
dent t tests and analyses of variance were used in univariate
analysis for binomial variables, and correlation coefficient
analyses were used for continuous variables. Multivariate
linear regression analysis was used in multivariate analysis.
A receiver operating characteristic (ROC) curve was used
to summarize the accuracy of tumor enhancement on
CECT and to evaluate the true-positive rate against the
false-positive rate for the different possible cutoff points
of the CECT attenuation value. The area under the curve
(AUC) was calculated. According to the different cutoff
Original Article
2334 Cancer May 15, 2010
points, sensitivity, specificity, positive predictive value,
and negative predictive value were calculated.
To evaluate the time to response of individual meta-
static lesions, we used the Kaplan-Meier method and a
Cox regression model in univariate survival analysis and a
Cox hazard regression model in multivariate survival anal-
ysis. The time to size reduction was defined as the time
from the initiation of TKIs to a reduction >30% in the
initial tumor size. The second endpoint of the study was
the time to progression of individual metastatic lesions,
which was defined as the time from the initiation of TKIs
to an increase >20% in the initial tumor size. The
Kaplan-Meier method and a Cox regression model used
in univariate survival analysis, and a multivariate Cox haz-
ard regression model was used in multivariate survival
analysis.
To control for individual confounding factors in the
analysis of metastatic tumors, tumor variables were
adjusted with respect to the patient variables using multi-
variate analysis. Patient variables were used only for statis-
tical adjustment and, thus, were not interpreted as
predictors. All multivariate analyses used variables that
were significant (P < .05) in the univariate analyses. Sta-
tistical analyses were performed using the Statistical Pack-
age for Social Sciences, version 17.0 for Windows (SPSS
Inc., Chicago, Ill). All tests were 2-sided and performed at
the 5% significance level.
RESULTS
Patient Characteristics
Table 1 lists the clinical and pathologic characteristics of
the 46 patients. The median follow-up was 15 months
(range, 3-40 months), and the median number of cycles
of TKI therapy was 4 (range, 2-13 cycles). Overall, 14
patients (30.4%) responded to TKI therapy. There
were no complete responses; however, a partial response
was observed in 14 patients (30.4%). Stable disease was
observed in 17 patients (40.0%), and progression was
observed in 15 patients (37.5%). In 22 patients (47.8%),
the responses were identical for all individual metastases;
however, in 24 patients (52.2%), the responses of individ-
ual metastatic lesions varied, with mixed responses
observed among patients who had lesions within the same
organ. In addition, responding and nonresponding lesions
within the same organ occurred in 10 patients (21.7%),
and lesions of increasing and decreasing size were observed
in 12 patients (26.1%).
Characteristics of Metastatic Tumors
Table 2 lists the radiologic characteristics of 198 meta-
static lesions. Tumor size was reduced in 140 lesions
(70.7%) and increased in 58 lesions (29.3%). The mean
(standard deviation) reduction in size was 23.8% 
56.6%. Tumor size was reduced by >30% in 91 meta-
static lesions (46%) and by>50% in 63 metastatic lesions
(31.8%). Ninety-three lesions (47%) remained stable,
and 27 lesions (13.6%) progressed. The mean (standard
Table 1. Patient Characteristics
Characteristic No. of
Patients (%)
Total 46 (100)
Sex
Men 33 (71.7)
Women 13 (28.3)
Median age [range], y 59 [32-74]
Karnofsky performance status, %
90 18 (39.1)
80 16 (34.8)
70 8 (17.4)
60 4 (8.7)
Histologic type
Primary renal tumor
Clear cell 37 (80.4)
Clear cell with SD 2 (4.3)
Mixed 7 (15.2)
Metastases
Clear cell 24 (52.2)
Clear cell with SD 3 (6.5)
Mixed 1 (2.2)
Unclassified 9 (19.6)
Insufficient or missing data 9 (19.6)
Median no. of metastases [range] 4 [1-30]
Removal of primary tumor
Cytoreductive nephrectomy 30 (65.2)
No removal 16 (34.8)
History of cytokine-based therapy
IL-2 and IFN-a 11 (23.9)
IFN-a 11 (23.9)
No history 24 (52.2)
Type of tyrosine-kinase inhibitor
Sunitinib 29 (63)
Sorafenib 17 (37)
Baseline serum laboratory
findings: Median [range]
Hemoglobin, g/dL 11.4 [7.6-18.3]
Total calcium, mg/dL 9.3 [7.9-11.3]
Corrected calcium, mg/dL 8.7 [7.7-11.1]
Lactate dehydrogenase, U/L 174 [88-792]
SD indicates sarcomatoid differentiation; IL-2, interleukin-2; IFN- a, inter-
feron alpha.
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deviation) values of tumor enhancement in responded
and nonresponded lesions were statistically different (70.7
 33.46 HU and 39.85  25.99 HU; respectively; P <
.001). Two cases that represent the changes in high-atte-
nuated and low-attenuated lesions during the therapy are
presented in Figure 1. The overall mean values for the
time to response and the time to progression were 8.6
months (95% confidence interval [CI], 7.4-9.9 months)
and 16.4 months (95% CI, 15.2-17.7 months), respec-
tively (Fig. 2).
Objective Responses
In univariate analyses, tumor growth pattern (P ¼ .005),
tumor size (P ¼ .007), and tumor enhancement (P <
.001) were associated with objective response, but necrosis
(P ¼ .788) and enhancement pattern (P ¼ .376) were
not. Multivariate logistic regression analyses adjusted for
the patient parameters revealed that contrast enhancement
(odds ratio [OR], 1.037; 95% CI, 1.013-1.062; P ¼
.003) and enhancement pattern (OR, 4.602; 95% CI,
1.176-18.008; P ¼ .028) were associated with objective
response (data not shown). ROC curves of contrast
enhancement were constructed and are depicted in Figure
3. Sensitivity and specificity were calculated according to
several cutoff points using the ROC curve, and the AUC
was 0.754 (95%CI, 0.688-0.821; P< .001).
Tumor Size Reduction
In univariate analyses, only contrast enhancement was
associated with maximal size reduction of metastatic
lesions (P < .001). The linear association between con-
trast enhancement and tumor size reduction is depicted in
Figure 4. Tumor growth pattern (P ¼ .059), necrosis (P
¼ .490) and enhancement pattern (P ¼ .608) were not
associated with tumor size reduction. In the multivariate
linear regression analysis, only contrast enhancement was
associated independently with tumor size reduction rate
(Table 3).
Time to Response
In univariate analyses of the time to response, tumor size
(hazard ratio [HR], 0.971; 95% CI, 0.951-0.991; P ¼
.05) and contrast enhancement (HR, 1.011; 95% CI,
1.006-1.016; P< .001) were associated with the time to a
30% size reduction, but growth pattern (P ¼ .157), ne-
crosis (P ¼ .96), and enhancement pattern (P ¼ .982)
were not. Multivariate Cox proportional hazard models
adjusted for patient variables indicated that only contrast
enhancement was associated significantly with the time to
response (Table 4).
Time to Disease Progression
In univariate analyses of progression-free survival for indi-
vidual metastatic lesions, tumor growth pattern (P ¼
.017) and contrast enhancement (P ¼ .007) were associ-
ated significantly with the time to progression, but necro-
sis (P ¼ .962), enhancement pattern (P ¼ .386), and
tumor size (P¼ .373) were not. Multivariate Cox propor-
tional hazard models revealed that only contrast enhance-
ment was associated with the time to progression of
individual metastatic lesions (Table 5).
Table 2. Characteristics of Individual Metastatic Lesions
Characteristic No. of
Patients (%)
Total 198 (100)
Sites
Lung 85 (42.9)
Mediastinum 41 (20.7)
Lymph node 22 (11.1)
Pleura 18 (9.1)
Bone 10 (5.1)
Muscles 6 (3)
Adrenal gland 6 (3)
Liver 4 (2)
Others 6 (3)
Size, mm
Mean 6 SD 22.2  15.1
Median [range] 17.8 [10.0-110.9]
Growth pattern
Conglomerated 173 (87.4)
Infiltrative 25 (12.6)
Necrosis
Absent 162 (81.8)
Present 36 (18.2)
Enhancement pattern
Homogenous 152 (76.8)
Heterogeneous 46 (23.2)
Contrast enhancement on CT, HU
Attenuation value at pre-enhanced phase
Mean 6 SD 36.3  18.7
Median [range] 33.0 [5.0 to 130.0]
Attenuation value at enhanced phase
Mean 6 SD 90.5  39.7
Median [range] 89.5 [5-222]
Difference in attenuation values
Mean 6 SD 54.2  35.9
Median [range] 48.5 [5-186]
SD indicates standard deviation; CT, computed tomography; HU, Houns-
field units.
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Treatment Outcomes According
to Tumor Enhancement
All metastatic lesions were classified into 4 groups accord-
ing to the degree of tumor enhancement. Table 6 shows
the overall relation between tumor enhancement and
treatment outcome. All lesions with a tumor enhancement
125 HU had a nearly complete response, whereas partial
responses were obtained in most lesions (70%) that had
tumor enhancement between 70 HU and 125 HU. These
2 groups had a similar time to progression (Fig. 5). By
Figure 1. These photomicrographs illustrate the difference in response between lesions with high and low attenuation lesions. (A)
A baseline computed tomography (CT) scan (tumor size, 17.5 mm; tumor enhancement in Hounsfield units [DHU], 173 Hounsfield
units [HU]) reveals a pancreatic metastasis with a high attenuation value on an early phase contrast-enhanced CT (CECT) in 1
patient that disappeared on both (B) the initial follow-up CECT (tumor size, 13.2 mm; DHU, 44 HU) and (C) a sequential follow-up
CECT (complete response), whereas (D) a lung metastasis with a low attenuation value on an early phase CECT from another
patient (baseline CT: tumor size, 23.4 mm; DHU, 25 HU) progressed on (E) the initial follow-up CT (tumor size, 41.8 mm; DHU,
39.5 HU).
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contrast, lesions with a tumor enhancement between 30
HU and 70 HU had a significantly lower response rate
and a relatively short time to progression. Finally, most
lesions that had tumor enhancement <30 HU did not
respond to antiangiogenic treatment and rapidly pro-
gressed (Table 6) (Fig. 5).
DISCUSSION
Currently, targeted therapy is being incorporated into
treatment strategies for several advanced malignancies. In
the management of mRCC, the first choice of treatment
is shifting from cytokine-based therapy to targeted thera-
pies that are based mainly on the inhibition of tumor
Figure 2. These Kaplan-Meier curves illustrate (A) the time to
response and (B) the time to disease progression in meta-
static lesions.
Figure 3. This graph illustrates the receiver operating
characteristic curve of contrast enhancement for objective
response.
Figure 4. Correlations between tumor enhancement and
changes in tumor size for individual metastatic lesions are
shown. HU indicates Hounsfield units.
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angiogenic activity. Therefore, we postulated that pre-
treatment contrast enhancement of tumors, with the abil-
ity to reveal the tumor vascularity, might predict
treatment outcomes. To our knowledge, this is the first
study to demonstrate that tumor enhancement on CECT
independently predicts tumor response and prognosis af-
ter targeted therapy in individual mRCC lesions.
On the basis of multivariate analyses, contrast
enhancement of the tumor was correlated independently
with tumor size reduction and the time to response during
antiangiogenic therapy (Tables 3 and 4). In addition, con-
trast enhancement was associated with the time to pro-
gression in individual metastatic lesions (Table 5).
Although all multivariate analyses were adjusted for
patient factors, contrast enhancement was a statistically
significant predictor of treatment outcomes in metastatic
lesions. Finally, we demonstrated that objective responses
and the prognoses of individual metastatic lesions could
be predicted by measuring pretreatment tumor enhance-
ment in individual metastatic lesions (Table 6, Fig. 5).
These findings suggest that tumor enhancement, as meas-
ured by CECT, may be used to predict outcomes for met-
astatic lesions during targeted therapy in patients with
mRCC.
Several factors, such as vascularity, vascular density,
vascular permeability, and blood flow, affect contrast
uptake in tumors.15-20 These influences are not under-
stood completely and should be investigated further,
although several studies have demonstrated that contrast
enhancement in MRI mirrors the biologic and histologic
properties of tumor angiogenesis.15,17,18,24-26 These stud-
ies suggest the possibility of contrast enhancement as a
potent predictor for the response or prognosis of metasta-
ses in mRCC; however, to our knowledge, no study to
date has demonstrated this possibility using CECT in
patients with mRCC. The measurement of contrast
enhancement on CECT does not provide a quantitative
Table 3. Multivariate Linear Regression Analysis for the Final
Size Reduction Rate in Individual Metastatic Lesions
Covariate b 95% CI P
Karnofsky performance
status, %
60 — — —
70 0.087 0.145 to 032 .459
80 0.908 0.175-1.64 .016
90 0.667 0.052-1.283 .034
Histology of primary tumor
Clear cell — — —
Clear cell with SD 0.427 0.336 to 1.19 .27
Mixed 0.525 0.181-0.868 .003
Histologic type of metastasis
Clear cell — — —
Clear cell with SD 0.082 0.502 to 0.666 .78
Mixed 0.213 0.295 to 0.0821 .488
Unclassified 0.097 0.344 to 0.149 .435
Removal of primary tumor
No removal — — —
Cytoreductive nephrectomy 0.079 0.229 to 0.387 .611
Previous cytokine-based
therapy
No treatment — — —
IFN-a 0.349 0.021-0.676 .037
IL-2 and IFN-a 0.292 0.586 to 0.02 .052
Site
Lung — — —
Mediastinum 0.054 0.189 to 0.297 .661
Pleura 0.215 0.209 to 0.639 .317
Lymph node 0.174 0.146 to 0.495 .284
Adrenal 0.035 0.479 to 0.409 .876
Bone 0.288 0.243 to 0.819 .284
Liver 0.402 0.279 to 1.084 .244
Hemoglobin 0.034 -0.031 to 0.099 .297
Corrected calcium 0.058 0.332 to 0.448 .769
Tumor enhancement 0.004 0.007 to 0.001 .004
CI indicates confidence interval; SD, sarcomatoid differentiation; IFN-a,
interferon alpha; IL-2, interleukin-2.
Table 4. Multivariate Cox Proportional Hazards Models for the
Time to Response in Individual Metastatic Lesions
Covariate HR 95% CI P
Karnofsky performance
status, %
60 — — —
70 0.450 0.125-1.626 .223
80 1.741 0.629-4.815 .285
90 0.457 0.234-0.890 .022
Histology of primary tumor
Clear cell — — —
Clear cell with SD 0.076 0.013-0.453 .005
Mixed 0.398 0.086-1.845 .239
Site
Lung — — —
Mediastinum 0.216 0.102-0.458 <.001
Pleura 0.923 0.304-2.807 .888
Lymph node 0.647 0.300-1.392 .265
Adrenal 0.095 0.019-0.478 .004
Bone 0.152 0.019-1.233 .078
Muscle .0659 0.763-5.668 .157
Others 0.659 0.198-2.194 .497
Hemoglobin 1.220 1.061-1.402 .005
Corrected calcium 6.055 2.021-18.136 .001
No. of metastasis 1.072 1.018-1.128 .008
Tumor size 0.990 0.966-1.014 .401
Tumor enhancement 1.009 1.001-1.016 .03
HR indicates hazard ratio; CI, confidence interval; SD, sarcomatoid
differentiation.
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evaluation of kinetic variables, such as flow contribution,
permeability, and extracellular volume fraction. Dynamic
CECT or MRI may be more appropriate for evaluating
these variables with respect to angiogenic activity. How-
ever, in clinical practice, CECT is used as a fairly standard
protocol for measuring tumor vascularity. Furthermore,
although several studies have demonstrated that measures
using MRI are promising for the evaluation of tumor vas-
cularity, the resolution of MRI is lower than that of CT
for lung and abdominal organs, indicating that MRI is of
limited use in evaluating metastases. However, CECT is
the most commonly used follow-up method for serial
changes in tumor lesions during treatment, and measures
of tumor enhancement on CECT are included in the rou-
tine evaluation of tumor lesions in clinical practice and
require no invasive tests or further processes.
Our findings may have significant clinical implica-
tions. Variable responses of multiple metastases frequently
are observed in patients undergoing systemic therapies.
Genetically, metastases are heterogeneous in several
malignancies, including RCC.27 Even primary RCCs that
grow with extensive angiogenesis can have metastases that
express distinct angiogenic and nonangiogenic growth
patterns.28 The heterogeneity of metastases also was appa-
rent in our study population, and many patients had vari-
able contrast enhancement of their metastatic tumors.
Because blood vessels are subject to the influence of the
local microenvironment and cytokines produced by tu-
mor cells,14 clinical factors like serum VEGF levels are
promising for predicting outcomes of antiangiogenic
therapies for metastases from clear cell RCC. However,
levels cannot predict the heterogeneous responses of meta-
static tumors. Our results demonstrate that measures of
contrast enhancement allow pretreatment prediction of
outcomes for individual metastatic lesions during targeted
therapy and may be useful for improving the selection of
lesions that will benefit from targeted therapy in the treat-
ment of mRCC.
The variability of contrast enhancement demon-
strated in the current study means that, given the hetero-
geneity in the angiogenic dependency of individual
metastatic tumors, which may be responsible for the fail-
ure of some antiangiogenic trials, and the nonangiogenic
growth patterns of some metastases, such tumors probably
would not respond to antiangiogenic agents.28 In our
study, 10 patients (21.7%) had both responding and
Table 5. Multivariate Cox Proportional Hazards Models for the
Time to Disease Progression in Individual Metastatic Lesions
Covariate HR 95% CI P
Age 0.980 0.952-0.995 .015
Karnofsky performance status, %
60 — — —
70 4.574 0.563-37.138 .155
80 10.771 0.656-176.738 .096
90 4.128 0.634-26.863 .138
Histology of primary tumor
Clear cell — — —
Clear cell with SD 67.294 2.194-206.691 .016
Mixed 7.920 2.124-29.531 .315
Removal of primary tumor
Not performed — — —
Performed 0.349 0.045-2.712 .315
Previous cytokine-based therapy
No treatment — — —
IFN-a 2.241 0.765-6.525 .142
IL-2 and IFN-a 0.273 0.018-4.032 .344
Hemoglobin 0.947 0.636-1.410 .790
Lactate dehydrogenase 0.997 0.991-1.003 .290
No. of metastasis 1.065 0.940-1.208 .324
Tumor growth pattern
Conglomerated type — — —
Infiltrative type 2.234 0.765-6.525 .142
Tumor enhancement 0.973 0.952-0.995 .015
HR indicates hazard ratio; CI, confidence interval; SD, sarcomatoid differ-
entiation; IFN-a, interferon alpha; IL-2, interleukin-2.
Table 6. Differences in Treatment Outcomes According to the Degree of Tumor Enhancement in Metastatic
Renal Cell Carcinoma Lesions
Tumor Enhancement,
DHU
No. of
Lesions
No. of Objective
Responses (%)a
Mean 6 SD Size
Reduction, %b
PFS Rate at
1 Year, %c
125 9 9 (100) 90.9  18.2 [] 100
From 70 to <125 45 32 (71.1) 53.2  48.2 [] 92.8
From 30 to <70 98 46 (46.9) 20.4  53 [] 66.7
<30 46 5 (10.9) 11.5  50.4 [þ] 57.2
SD indicates standard deviation; DHU indicates tumor enhancement in Hounsfield units; [], decrease; [þ], increase.
aP < .001 (chi-square test).
bP < .001 (analysis of variance).
c Kaplan-Meier curves, as depicted in Figure 5, were compared.
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nonresponding lesions. In 12 patients (26.1%), lesions of
increasing size were present simultaneously with other
lesions of decreasing size. The majority of clear cell RCCs
have biallelic von Hippel-Lindau gene inactivation, which
results in the overexpression of growth factors, including
VEGF, allowing the hypervascular characteristics of RCC
and a favorable response to antiantiogenic therapy29;
whereas metastatic lesions may have tumor characteristics
that differ from those of a primary renal tumor even
within the same patient, because genetically diverse cancer
cells can be seeded by the primary tumor, and genetic
changes also can occur in the process of disease progres-
sion and metastases. Genetic heterogeneity of metastatic
clones and diverse microenvironments supporting meta-
static growths seem to allow different response patterns to
antiangiogenic therapy. However, the exact mechanism
should be investigated further.
Current strategies for cancer treatment tend to focus
excessively on a patient’s overall outcome. The RECIST,
currently the most commonly used criteria for response,
overcome this weakness by using the sum of the greatest
tumor dimensions, but these criteria are insufficient for
the individual evaluation of heterogeneous responses
within a patient. In our study, some patients stopped
using TKIs because a small number of metastases pro-
gressed, although most metastases responded well or were
stable during TKI therapy. Metastasectomy after targeted
therapy or after combination therapy with other agents
might play a vital role in this patient population and is
worthy of investigation.30 These findings reflect the need
to treat individual metastases in mRCC with multidisci-
plinary approaches that are chosen according to the char-
acteristics of individual metastatic lesions before
treatment is initiated. Our analysis using classification
according to tumor enhancement suggests that lesional
approaches, through the measurement of pretreatment
contrast enhancement values, may be useful in outcome
prediction and treatment selection.
Our study has limitations. Because of the retrospec-
tive nature of the study and our small cohort, we cannot
rule out a possible bias in patient selection. In a significant
number of patients, there was a high correlation between
responses in different lesions within a patient rather than a
heterogeneous response. We addressed this possible
patient-based difference in tumor response by adjusting the
tumor (lesion) variables based on patient variables by using
multivariate analyses. Nevertheless, patient-based rather
than lesion-based differences cannot be ruled out, and this
is a limitation in this study design. A statistical model
explaining the correlation among lesions remains to be
established. In addition, survival analyses could not be per-
formed, because the follow-up period was not long enough.
Therefore, the significance of tumor enhancement in pre-
dicting overall survival and the cutoff point that can differ-
entiate metastatic lesions with a good prognosis from those
with a poor prognosis in patients with mRCC should be
investigated further. Future prospective studies with long-
term follow-up will be required to confirm our findings.
In summary, tumor enhancement on CECT was
associated with tumor size reduction, time to response,
and time to progression of individual metastases in
patients with mRCC who received targeted therapy. Ini-
tial tumor enhancement on CECTmay be useful as a clin-
ical predictor during targeted therapy and to improve the
selection of patients who may benefit from targeted ther-
apy in the treatment of mRCC.
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